The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Tourette Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tourette Syndrome


Psychiatry related information on Tourette Syndrome


High impact information on Tourette Syndrome


Chemical compound and disease context of Tourette Syndrome


Biological context of Tourette Syndrome


Anatomical context of Tourette Syndrome


Gene context of Tourette Syndrome


Analytical, diagnostic and therapeutic context of Tourette Syndrome


  1. Segmental linkage disequilibrium within the dopamine transporter gene. Greenwood, T.A., Alexander, M., Keck, P.E., McElroy, S., Sadovnick, A.D., Remick, R.A., Shaw, S.H., Kelsoe, J.R. Mol. Psychiatry (2002) [Pubmed]
  2. 9p monosomy in a patient with Gilles de la Tourette's syndrome. Taylor, L.D., Krizman, D.B., Jankovic, J., Hayani, A., Steuber, P.C., Greenberg, F., Fenwick, R.G., Caskey, C.T. Neurology (1991) [Pubmed]
  3. Cognitive-pharmacologic functional magnetic resonance imaging in tourette syndrome: a pilot study. Hershey, T., Black, K.J., Hartlein, J.M., Barch, D.M., Braver, T.S., Carl, J.L., Perlmutter, J.S. Biol. Psychiatry (2004) [Pubmed]
  4. The coexistence of tics and dystonia. Stone, L.A., Jankovic, J. Arch. Neurol. (1991) [Pubmed]
  5. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. Stahl, S.M., Davis, K.L., Berger, P.A. Journal of clinical psychopharmacology. (1982) [Pubmed]
  6. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. Comings, D.E., Comings, B.G., Muhleman, D., Dietz, G., Shahbahrami, B., Tast, D., Knell, E., Kocsis, P., Baumgarten, R., Kovacs, B.W. JAMA (1991) [Pubmed]
  7. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Spencer, T., Biederman, J., Coffey, B., Geller, D., Crawford, M., Bearman, S.K., Tarazi, R., Faraone, S.V. Arch. Gen. Psychiatry (2002) [Pubmed]
  8. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Blum, K., Braverman, E.R., Wu, S., Cull, J.G., Chen, T.J., Gill, J., Wood, R., Eisenberg, A., Sherman, M., Davis, K.R., Matthews, D., Fischer, L., Schnautz, N., Walsh, W., Pontius, A.A., Zedar, M., Kaats, G., Comings, D.E. Mol. Psychiatry (1997) [Pubmed]
  9. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Biederman, J., Newcorn, J., Sprich, S. The American journal of psychiatry. (1991) [Pubmed]
  10. Correlation of length of VNTR alleles at the X-linked MAOA gene and phenotypic effect in Tourette syndrome and drug abuse. Gade, R., Muhleman, D., Blake, H., MacMurray, J., Johnson, P., Verde, R., Saucier, G., Comings, D.E. Mol. Psychiatry (1998) [Pubmed]
  11. Cocaine and Tourette's syndrome. Mesulam, M.M. N. Engl. J. Med. (1986) [Pubmed]
  12. Treatment of Tourette's syndrome with RO22-1319, a D-2-receptor antagonist. Uhr, S.B., Berger, P.A., Pruitt, B., Stahl, S.M. N. Engl. J. Med. (1984) [Pubmed]
  13. Red-cell choline and Gilles de la Tourette syndrome. Hanin, I., Merikangas, J.R., Merikangas, K.R., Kopp, U. N. Engl. J. Med. (1979) [Pubmed]
  14. Purine phosphoribosyltransferase in gilles de la Tourette syndrome. Van Woert, M.H., Yip, L.C., Balis, M.E. N. Engl. J. Med. (1977) [Pubmed]
  15. HGPRT in the Gilles de la Tourette syndrome. Johnson, G.G., Pepple, J.M., Singer, H.S., Littlefield, J.W. N. Engl. J. Med. (1977) [Pubmed]
  16. The D2 dopamine receptor and Tourette's syndrome. Golwyn, D.H., Sevlie, C. JAMA (1992) [Pubmed]
  17. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Silver, A.A., Sanberg, P.R. Lancet (1993) [Pubmed]
  18. Clonidine in Tourette syndrome. McKeith, I.G., Williams, A., Nicol, A.R. Lancet (1981) [Pubmed]
  19. Comparison of pimozide with haloperidol in Gilles de la Tourette syndrome. Rose, M.S., Moldofsky, H. Lancet (1977) [Pubmed]
  20. Longlasting improvement of Tourette's syndrome with transdermal nicotine. Dursun, S.M., Reveley, M.A., Bird, R., Stirton, F. Lancet (1994) [Pubmed]
  21. Linkage disequilibrium between an allele at the dopamine D4 receptor locus and Tourette syndrome, by the transmission-disequilibrium test. Grice, D.E., Leckman, J.F., Pauls, D.L., Kurlan, R., Kidd, K.K., Pakstis, A.J., Chang, F.M., Buxbaum, J.D., Cohen, D.J., Gelernter, J. Am. J. Hum. Genet. (1996) [Pubmed]
  22. Exclusion of close linkage of Tourette's syndrome to D1 dopamine receptor. Gelernter, J., Kennedy, J.L., Grandy, D.K., Zhou, Q.Y., Civelli, O., Pauls, D.L., Pakstis, A., Kurlan, R., Sunahara, R.K., Niznik, H.B. The American journal of psychiatry. (1993) [Pubmed]
  23. Neuroreceptor subunit genes and the genetic susceptibility to Gilles de la Tourette syndrome. Brett, P.M., Curtis, D., Robertson, M.M., Gurling, H.M. Biol. Psychiatry (1997) [Pubmed]
  24. Dopamine D2 receptor gene (DRD2) haplotypes and the defense style questionnaire in substance abuse, Tourette syndrome, and controls. Comings, D.E., MacMurray, J., Johnson, P., Dietz, G., Muhleman, D. Biol. Psychiatry (1995) [Pubmed]
  25. Assignment of the 5HT7 receptor gene (HTR7) to chromosome 10q and exclusion of genetic linkage with Tourette syndrome. Gelernter, J., Rao, P.A., Pauls, D.L., Hamblin, M.W., Sibley, D.R., Kidd, K.K. Genomics (1995) [Pubmed]
  26. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., Pauls, D.L., Anderson, G.M., Riddle, M.A., McSwiggan-Hardin, M., McDougle, C.J. Arch. Gen. Psychiatry (1994) [Pubmed]
  27. Huntington disease and Tourette syndrome. II. Uptake of glutamic acid and other amino acids by fibroblasts. Comings, D.E., Goetz, I.E., Holden, J., Holtz, J. Am. J. Hum. Genet. (1981) [Pubmed]
  28. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Singer, H.S., Szymanski, S., Giuliano, J., Yokoi, F., Dogan, A.S., Brasic, J.R., Zhou, Y., Grace, A.A., Wong, D.F. The American journal of psychiatry. (2002) [Pubmed]
  29. Controlled study of erythrocyte choline in Tourette syndrome. Sallee, F.R., Kopp, U., Hanin, I. Biol. Psychiatry (1992) [Pubmed]
  30. Behavioral laterality in individuals with Gilles de la Tourette's syndrome and basal ganglia alterations: a preliminary report. Yazgan, M.Y., Peterson, B., Wexler, B.E., Leckman, J.F. Biol. Psychiatry (1995) [Pubmed]
  31. Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome. Petek, E., Windpassinger, C., Vincent, J.B., Cheung, J., Boright, A.P., Scherer, S.W., Kroisel, P.M., Wagner, K. Am. J. Hum. Genet. (2001) [Pubmed]
  32. Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Vandenbergh, D.J., Thompson, M.D., Cook, E.H., Bendahhou, E., Nguyen, T., Krasowski, M.D., Zarrabian, D., Comings, D., Sellers, E.M., Tyndale, R.F., George, S.R., O'Dowd, B.F., Uhl, G.R. Mol. Psychiatry (2000) [Pubmed]
  33. A mannosyltransferase gene at 11q23 is disrupted by a translocation breakpoint that co-segregates with bipolar affective disorder in a small family. Baysal, B.E., Willett-Brozick, J.E., Badner, J.A., Corona, W., Ferrell, R.E., Nimgaonkar, V.L., Detera-Wadleigh, S.D. Neurogenetics (2002) [Pubmed]
  34. Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Comings, D.E., Gade-Andavolu, R., Gonzalez, N., Blake, H., Wu, S., MacMurray, J.P. Clin. Genet. (1999) [Pubmed]
  35. Mutation screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol dependent patients. Thompson, M., Comings, D.E., Feder, L., George, S.R., O'Dowd, B.F. Am. J. Med. Genet. (1998) [Pubmed]
  36. Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Goetz, C.G., Tanner, C.M., Wilson, R.S., Carroll, V.S., Como, P.G., Shannon, K.M. Ann. Neurol. (1987) [Pubmed]
  37. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Sallee, F.R., Nesbitt, L., Jackson, C., Sine, L., Sethuraman, G. The American journal of psychiatry. (1997) [Pubmed]
  38. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Fulop, G., Phillips, R.A., Shapiro, A.K., Gomes, J.A., Shapiro, E., Nordlie, J.W. The American journal of psychiatry. (1987) [Pubmed]
  39. The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome. Gelernter, J., Vandenbergh, D., Kruger, S.D., Pauls, D.L., Kurlan, R., Pakstis, A.J., Kidd, K.K., Uhl, G. Genomics (1995) [Pubmed]
  40. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Serra-Mestres, J., Ring, H.A., Costa, D.C., Gacinovic, S., Walker, Z., Lees, A.J., Robertson, M.M., Trimble, M.R. Acta psychiatrica Scandinavica. (2004) [Pubmed]
WikiGenes - Universities